Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
Type II Diabetes Mellitus, Dyslipidemia
About this trial
This is an interventional treatment trial for Type II Diabetes Mellitus focused on measuring Kowa, Type II Diabetes Mellitus, Combined Dyslipidemia, pitavastatin, NK-104, Atorvastatin
Eligibility Criteria
Inclusion Criteria: Males and females (ages 18-75 years) Type II DM treated with oral anti-diabetic medication (sulfonylurea, metformin, glitazones, or combination therapy) Must have been following a restrictive diet Diagnosis of combined dyslipidemia Exclusion Criteria: Homozygous familial hypercholesterolemia Conditions which may cause secondary dyslipidemia Uncontrolled diabetes mellitus Abnormal pancreatic, liver, or renal function Abnormal serum creatine kinase (CK) above the pre-specified level Significant heart disease
Sites / Locations
- CCBR Aalborg
- CCBR A/S
- CCBR Vejle
- Gemeinschaftspraxis am Bahnhof
- Pharmakologisches Studienzentum Chemnitz
- Internistische Diabetische Schwerpunktpraxis Dr.
- Internistische Gemeinschaftspraxis
- Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
- Bhagwan Mahaveer Jain Heart Centre
- Sri Ramachandra Medical College Hospital
- Apollo Hospitals
- CARE Group of Hospitals
- PD Hinduja Hospital
- Andromed Breda
- Andromed Eindhoven
- Andromed Noord
- Andromed Leiden
- Andromed Nijmegen
- Andromed Rotterdam
- Andromed Oost
- Andromed Zoetermeer
- Podlaski Osrodek Kardiologii
- NZOZ GCP Dobra Praktyka Lekaska
- NZOZ Terapia Optima
- NZOZ Esculap, Przychodnia Lekary Rodzinnych
- NZOZ Centrum, Poradnia Kardiologiczna
- Spec. Gab. Lek. Internistyczno-Kardiologicznly
- Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego
- Instytut Zywnosci i Zywienia
- Lecznica PROSEN SMO
- Szpital Wolski,im. Dr A. Gostynskiej
- Synexus Reading Clinical Research Centre
- Synexus Lancashire Clinical Research Centre
- Synexus Merseyside Clinical Research Centre
- Synexus Manchester Clinical Research Centre
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Pitavastatin 4 mg QD
Atorvastatin 20 mg QD
Pitavastatin 4 mg once daily
Atorvastatin 20 mg once daily